Navigation Links
DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
Date:2/4/2008

cal studies and the results obtained from those studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements t
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
3. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
4. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
7. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
8. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
9. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
10. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
11. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 The Lupus Foundation of ... LLY ) today released results from UNVEIL: understanding the ... on the lupus journey and the challenges not only ... caregivers. The UNVEIL study, which involved over 1,000 people ... lupus has on all aspects of life including family, ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... WORTH, Texas, March 22, 2012  The Board of Directors of ... innovator in advanced wound care solutions, announced today that Robert ... of the Company.  In addition, Scott A. Haire has resigned ... Executive Officer of the Company, and Deborah Jenkins Hutchinson has ...
... 22, 2012  Argon Medical Devices, Inc. announced today ... catheter, licensed from Rex Medical, LP, designed to ... treatments. "UltraStream provides clinicians with an ... life for their patients," commented George Leondis, President ...
Cached Medicine Technology:Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 2Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 3Argon Medical Devices Announces The Launch of a Unique New Chronic Hemodialysis Catheter 2
(Date:9/16/2014)... September 15, 2014A prospective study that compared patient-reported ... with bone metastases demonstrates that single fraction radiation ... fraction radiation therapy (MFRT) when pain, function and ... presented today at the American Society for Radiation ... indicates that improvements in patients, pain, function and ...
(Date:9/16/2014)... Poster and Poster Discussion abstracts to be presented at ... Wednesday, 17 September 2014 at 12:00 (CEST) to give ... from the European medical oncology Congress, under the leading ... at the point where genuinely targeted therapy is now ... medicine means we are all working towards a common ...
(Date:9/16/2014)... PA (PRWEB) September 16, 2014 ... Pain Management practice by Ranking Arizona magazine, has selected ... implementation across its enterprise. , With TPC seeing ... a vast data repository that was managed through “home ... both the management and clinical leadership teams. “Our ...
(Date:9/16/2014)... Albany, New York (PRWEB) September 16, 2014 ... intelligence firm states that the global facial care market ... billion by 2019. The report, titled ‘Facial Care Market ... Facial Creams, Face Wash, Cleansing Wipes, Serums and Masks ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming up with ... become the Presenting Sponsor of the 2014-15 and 2015-16 ... wellness partner. As the Presenting Sponsor for the next ... name inclusion on all Lightning advertising campaigns and materials ... a sponsorship partner of the Lightning since 2011, and ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:ESMO 2014 Congress Preview 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3
... business of recruiting,university students and new graduates is ... on this talent pool to,refresh the workforce with ... changed their university recruiting methods and programs,in decades ... a leading,pharmaceutical research firm., The study analyzes ...
... need to be aware of the connection, study says ... between diabetes and depression apparently cuts both ways: Not ... a heightened risk for developing depression, individuals with depression ... research revelation suggests that both doctors and patients need ...
... Foundation,announced the winners of its annual "Healthy Communities ... 10 at its offices in Edison, N.J.,Twelve New ... year,s,calendar and each received an iPOD shuffle., ... importance,of a healthy lifestyle and promotes awareness of ...
... Million in Savings in Past 4 Years, HARRISBURG, ... saving taxpayer funds, they should support,the Department of Public ... less for prescription drugs for children and families who ... Welfare,Estelle B. Richman said today., "Every budget season ...
... the University of Pennsylvania School of Medicine found that ... cell and developmental biology leads to an increase in ... therapies for lung-tissue repair after injury or disease. The ... of print publication in Nature Genetics . , ...
... Continues to Draw Top Research Institutes,Talent, and Corporate Labs That Are Looking ... ... Future, SAN DIEGO, June 17 /Xinhua-PRNewswire/ -- Singapore,s investment ... the fastest growing bioclusters in the world. R&D spending in the,biomedical sciences ...
Cached Medicine News:Health News:Best Practices: Achieving Excellence in Staffing and Recruiting Methods 2Health News:Diabetes and Depression Go Hand-in-Hand 2Health News:Diabetes and Depression Go Hand-in-Hand 3Health News:AMERIGROUP Foundation Announces Winners of 'Healthy Communities Art Project' 2Health News:PA Secretary of Public Welfare Urges General Assembly To Support Saving $100 Million Through Smarter Pharmacy Benefit Management 2Health News:PA Secretary of Public Welfare Urges General Assembly To Support Saving $100 Million Through Smarter Pharmacy Benefit Management 3Health News:Penn researchers find key developmental pathway activates lung stem cells 2Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 2Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 3Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 4Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 5Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 6
... ACS allows visualization of virtually the ... essentially coaxial positioning of the lens on ... detachment surgery, repairing giant retinal tears, diagnosing ... examining the peripheral retina in a vitreous ...
... somewhat higher magnification and increased ... best suited for detailed visualization ... Central Retinal is ideal for ... membrane peeling in proliferative vitreoretinopathy ...
... MiniQuad allows visualization of virtually the ... with essentially coaxial positioning of the ... excellent for retinal detachment surgery, repairing ... anterior proliferative vitreoretinopathy and for examining ...
... Lens enhances iridectomy procedures by providing ... conventional iridectomy lens designs) with exceptional ... this lens has been increased from ... The MagPlus comes standard with LaserWindow ...
Medicine Products: